GLP-1RAs are well-established for managing T2D and obesity (61,73,74), and exhibit emerging antitumor potential in related cancers, such as colorectal and endometrial cancers (75,76)
However, combining supplements with prescription medications always warrants a conversation with your prescriber, particularly given potential interactions with glucose-lowering medications
The trial results showed by those on the lowest dose cut their glycated haemoglobin level by an average of 1.24 percentage points compared to 1.47 percentage points with the 12-mg dose, and 1.48 percentage points on the 36-mg dose
Lilly Presents SURMOUNT-4 Trial Results Louis Aronne, the director of the Weill Cornell Medicine Comprehensive Weight Control Center in New York, presented the comprehensive findings of the SURMOUNT-4 trial at the European Association for the Study of Diabetes conference in Hamburg, Germany